AxoSim, a leading life science company based in New Orleans, has appointed Alif Saleh as their new CEO. Saleh brings a wealth of experience in raising $500 million for the development and commercialization of novel technologies in the life science and biotechnology industry. His previous roles include serving as CEO of Scipher Medicine Corporation and senior vice president of GC International Corporation.
As CEO, Saleh is expected to lead AxoSim into its next phase of growth by leveraging his expertise and strong commercial background. With a Master of Science degree in chemical and genetic engineering, he is well-equipped to drive the company forward.
Saleh emphasized the need for new technologies to increase success rates in drug development, particularly in neurology. AxoSim’s brain-on-a-chip platform utilizes tissue engineering, neural interfacing, and AI to test interventions in neurology and generate human-relevant data. By partnering with pharmaceutical companies, AxoSim aims to accelerate drug development in the field.
In addition to Saleh’s appointment, AxoSim has also brought on Drs. David Weiner and Dale Pfost as board co-chairs. Weiner has 30 years of drug discovery experience in neurology, having held leadership roles in various pharmaceutical companies. The company’s strategic partnerships, strong leadership team, and innovative technology position AxoSim for continued success in the life science industry.
Overall, AxoSim’s appointment of Alif Saleh as their new CEO marks a significant milestone for the company’s continued growth and success in the life science industry.
